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Abstract
Background: The aim of this study was to investigate if there is an association between different SNP combinations in 
the guanosine triphosphate cyclohydrolase (GCH1) gene and a number of pain behavior related outcomes during 
labor. A population-based sample of pregnant women (n = 814) was recruited at gestational week 18. A plasma sample 
was collected from each subject. Genotyping was performed and three single nucleotide polymorphisms (SNP) 
previously defined as a pain-protective SNP combination of GCH1 were used.
Results: Homozygous carriers of the pain-protective SNP combination of GCH1 arrived to the delivery ward with a 
more advanced stage of cervical dilation compared to heterozygous carriers and non-carriers. However, homozygous 
carriers more often used second line labor analgesia compared to the others.
Conclusion: The pain-protective SNP combination of GCH1 may be of importance in the limited number of 
homozygous carriers during the initial dilation of cervix but upon arrival at the delivery unit these women are more 
inclined to use second line labor analgesia.
Introduction
Labor is considered to be one of the most painful events
in human experience. The perceived pain during labor is
the result of a number of complex interactions involving
physiological mechanisms, i.e. type of onset and duration
of labor and the size of the fetus, as well as psychological
mechanisms such as previous pain experiences and sup-
port [1-3].
From clinical practice it is well-known that women
experience varying degrees of pain in labor, in turn rais-
ing the possibility that genetic predisposition may be of
importance for pain perception. Indeed, a number of
clinical studies have identified polymorphisms at several
gene loci that are associated with differential sensitivity to
experimental pain [4] and inbred strains of mice also dis-
play altered pain responses in models of neuropathic and
inflammatory pain [5-7]. These studies strongly suggest
that genetic factors play an important role underlying
mechanisms of experience of pain. Although research
within this field is limited in the obstetric setting, genetic
variability of the μ-opioid receptor has recently been
associated with intrathecal fentanyl analgesia require-
ments in laboring women [8].
It has recently been reported by Tegeder and colleagues
that specific SNPs in the guanosine triphosphate cyclohy-
drolase (GCH1) gene are associated with reduced pain
sensitivity in humans [9]. GCH1 is the rate limiting
enzyme in the biosynthesis of 6(R)-L-erythro-5,6,7,8-tet-
rahydrobiopterin (BH4) [10,11]. BH4, in turn, is an essen-
tial cofactor in the synthesis of many pain modulators
including catecholamines, serotonin and nitric oxide [12]
and feed-forward activation via phenylalanine and feed-
back inhibition through BH4 regulates the activity of
GCH1 [13]. The identified pain-protective SNP combina-
tion of GCH1 is composed of 15 SNPs found at different
locations on the gene [9]. Recently, screening for the
combination of three SNPs has been shown to be suffi-
cient for definition of the pain-protective haplotype with
high sensitivity and specificity: c.-9610G > A,
c343+8900A > T, and c.*4279 > G [14].
Genetic polymorphisms that are of importance for reg-
ulation of pain during labor are scarcely studied and the
importance of the pain-protective SNP combination of
GCH1 in laboring women is unknown. We hypothesized
that if genetic variability plays a clinically relevant role in
pain perception during labor, the pain-protective SNP
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combination of GCH1 would be associated with altered
use of labor analgesia and other pain behaviors in the
ordinary, routine care of laboring women.
The aim of this study was to investigate if there is an
association between the pain-protective SNP combina-
tion of GCH1 and a number of pain behavior related out-
comes during labor.
Results
Background characteristics
Among all eligible women, 814 (approximately 65%)
accepted to participate in the study. Genotyping was
completed in 811 subjects. Of the 811 women with com-
plete genotyping, 31 (3.8%) women delivered elsewhere,
53 (6.5%) were delivered by planned caesarean section,
and 22 (2.7%) women were delivered by acute caesarean
section before onset of labor. Three subjects who deliv-
ered before gestational week 30 and one subject with
intrauterine fetal death were excluded. Consequently, 701
women entered active phase of labor and among these
676 were of Caucasian origin. Analyses were conducted
in Caucasians only.
Genotyping of the pain-protective SNP combination of 
GCH1
Among the 676 Caucasian subjects who had complete
data on the SNP analyses in the study population, 15
(2.2%) were homozygous carriers, 180 (26.6%) heterozy-
gous carriers and 481 (71.1%) were non-carriers of the
pain-protective SNP combination of GCH1.
Demographic data and clinical variables for homozy-
gous carriers, heterozygous carriers and non-carriers of
the pain-protective SNP combination of GCH1 are given
in Table 1. There were no major differences in sociode-
mographic and clinical variables between groups. Pain
behavior related outcomes for homozygous carriers,
heterozygous carriers and non-carriers of the pain-pro-
tective SNP combination of GCH1 are given in Table 2.
Homozygous carriers of the GCH1 pain-protective SNP
combination arrived in the delivery ward with a more
advanced stage of cervical dilation than subjects
heterozygous for the pain-protective SNP combination
and non-carriers did (F(2,591) = 3.42; p = 0.033, adjusted
for parity).
GCH1 and use of Labor Analgesia
A possible association between the pain-protective SNP
combination of GCH1 and use of second line analgesia
was suggested by the bivariate analysis (p = 0.10). This
possible association was further analyzed with adjust-
ment for possible confounders in a multivariate logistic
regression model.
Factors associated with use of second line labor analge-
sia are given in Table 3. In the bivariate analyses nullipar-
ity, induced labor, slight cervical dilation upon arrival in
the delivery unit, and duration of labor were associated
with second line labor analgesia. Independent explana-
tory factors for use of second line labor analgesia use
were nulliparity, < 2 cm dilation of cervix at arrival in the
delivery unit and duration of labor for more than 2 hours.
Homozygous carriers of the pain-protective SNP combi-
nation had an increased risk of using second line labor
analgesia, whereas heterozygous carriers did not differ in
this aspect from non-carriers.
81 subjects lacked data on cervical dilation at arrival to
the delivery department. However, if cervical dilation was
removed from the multivariate analysis, the odds ratio for
homozygous carriers' use of second line labor analgesia
was unchanged (OR 4.59, 95% CI 1.07 - 19.73).
Discussion
Even though carriers of the pain-protective SNP combi-
nation of GCH1 in previous studies have been shown to
be less sensitive to pain, the major finding of the present
study was that this specific pain-protective SNP combi-
nation did not dramatically change pain perception or
behavior during labor. Heterozygous carriers of the pain-
protective SNP combination of GCH1 did not differ in
any aspect from non-carriers in the possible pain behav-
ior related outcomes of the study. Homozygous carriers
of the pain-protective SNP combination of GCH1 com-
prised only 2.2% of the population-based sample but
appeared to arrive in the delivery ward with a more
advanced stage of cervical dilation than heterozygous and
non-carriers did. This finding possibly indicates an
increased tolerance to pain in the early stages of labor.
However, once they arrived at the delivery ward, women
with the pain-protective SNP combination were more
inclined to use second line labor analgesia compared with
heterozygous carriers and non-carriers.
The literature on the pain-protective SNP combination
of GCH1 is conflicting and the pain-protective effect
appears to be most evident in patients with neuropathic
rather than nociceptive pain. Tegeder and colleagues [9]
suggested that the pain-protective SNP combination is
associated with less pain following discectomy for persis-
tent radicular low back pain and their results have later
been reproduced both by themselves [14] and by others
[15]. Further studies on the pain-protective SNP combi-
nation of GCH1 have been more discouraging. Kim and
colleagues [16] found no association between rated pain
severity after surgical removal of molar teeth and the
pain-protective SNP combination of GCH1, and similar
negative findings were obtained in patients with chronic
pancreatitis [17]. Presumably, the negative results in our
study could be due to the fact that labor pain is mainly
nociceptive or that pain modulating pathways affected by
BH4 are not the primary ones during labor [12].Dabo et al. Molecular Pain 2010, 6:41
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Pain during the first stage of labor is nociceptive and
caused by distension of the lower uterine segment, dila-
tion of cervix and the uterine muscle contractions. A
number of neurotransmitters and chemical mediators are
involved in the signaling, modulation, and perception of
pain including bradykinin, catecholamines, serotonin,
substance P, and nitric oxide [1,18]. In the second phase
of labor the pain is also mainly nociceptive and arises
from pressure on the vagina, vulva and perineum, medi-
ated through the pudendal nerve. However, neuropathic
pain from direct pressure on the lumbosaccral plexus is
also of importance in this phase [18].
Another reason for the firm lack of results in our study
could be due to the fairly blunt measures of pain percep-
tion and pain behavior that were used. If more detailed
and specified protocols for labor analgesia had been used
it is possible that more subtle differences between the dif-
ferent SNP combinations, and especially among the
homozygous carriers, could have been revealed. How-
e v e r ,  e v e n  t h o u g h  o u r  m e a s u r e s  o f  p a i n  s e v e r i t y  w e r e
Table 1: Demographic data and clinical characteristics of the study population, according to GCH1 pain protecting 
haplotypes.
Non-carriers
(n = 481)
Heterozygous
(n = 180)
Homozygous
(n = 15)
Age, years 30.67 ± 4.9 31.0 ± 4.6 31.4 ± 5.1
BMI at first antenatal visit, kg/m2 24.2 ± 4.0 24.6 ± 4.3 22.3 ± 2.5
Pre-pregnancy smokers, n (%)a 52 (11.0%) 23 (13.1%) 3 (21.4%)
Married/cohabiting, n (%) 457 (95.0%) 169 (93.8%) 15 (100%)
Nulliparity, n (%) 221 (45.9%) 72 (40.0%) 10 (66.7%)
Singleton pregnancies 476 (99.0%) 180 (100%) 15 (100%)
Spontaneous start of delivery 411 (85.4%) 156 (86.7%) 13 (86.7%)
Gestational week 39.4 ± 1.5 39.3 ± 1.7 39.9 ± 1.3
Duration of labor, hours 7.4 ± 7.2 6.5 ± 5.7 6.5 ± 4.7
Use of oxytocin 219 (45.5%) 76 (42.2%) 7 (46.7%)
Vaginal delivery 405 (84.3%) 157 (87.2%) 12 (80.0%)
Vacuum extraction 53 (11.0%) 12 (6.7%) 1 (6.7%)
Caesarean section 23 (4.8%) 11 (6.1%) 2 (13.3%)
a missing data in 13 subjects
Table 2: Labor pain behavior related outcomes according to GCH1 haplotypes
Non-carriers
(n = 481)
Heterozygous
(n = 180)
Homozygous
(n = 15)
Cervical dilation at arrival to the delivery unita, cm 4.3 ± 2.5 4.1 ± 2.3 5.7 ± 2.2*
Cervical dilation at request of epidural analgesiab, cm 5.8 ± 1.9 5.3 ± 2.0 6.3 ± 2.3
Use of labor analgesia, n (%) No use 44 (9.1%) 17 (9.4%) 1 (6.7%)
Nitrous oxide 396 (82.3%) 143 (79.4%) 12 (80.0%)
Acupuncture 155 (32.2%) 62 (34.4%) 6 (40.0%)
Epidural analgesia 159 (33.1%) 52 (28.9%) 7 (46.7%)
Second line 
analgesia
249 (51.8%) 92 (51.1%) 11 (73.3%)
*p = 0.033 in comparison to heterozygous carriers and non-carriers of the GCH1 haplotype, ANOVA adjusted for parity.
a Data missing in 81 subjects
b Data based on 159 non-carriers, 52 heterozygous and 7 homozygous carriers of the GCH1 haplotype.Dabo et al. Molecular Pain 2010, 6:41
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blunt they serve a purpose. If genetic variability plays a
clinically relevant role in pain perception during labor
that would justify pre-labor testing and counseling, the
pain-protective genotype or haplotype of interest needs
to prove itself in the ordinary, routine care of laboring
women.
An increasing number of studies strongly suggest that
genetic predisposition plays an important role in pain
mechanisms [4], and although research is limited within
the obstetric setting, it is plausible that certain pain-pro-
tective genotypes may contribute to the varying degree of
perceived pain and/or pain behavior during labor.
Recently homozygous carriers of the pain-protective
304G/G allele of the μ-opioid receptor were shown to
require significantly less fentanyl for labor analgesia but
also requested analgesia at a more advanced stage of cer-
vical dilation [8].
Given that we only found signs of altered pain sensitiv-
ity among homozygous carriers of the pain-protective
SNP combination of GCH1, the major limitation of our
study is the number of women included. However, the
results among the heterozygous carriers must be consid-
ered to be fairly robust. On the other hand, one of the
strengths of the study is the homogenous population-
based sample where Caucasians dominate. There is a
known ethnic difference in pain sensitivity and genotype
frequencies of the pain-protective SNP combination of
GCH1 [16]. Kim and co-workers has shown that a
homogenous population of a cohort is needed to avoid
population stratification [16].
Conclusions
In conclusion, our study indicates that the pain-protec-
tive SNP combination of GCH1 may be of importance in
a limited number of homozygous carriers during the ini-
tial dilation of cervix but upon arrival at the delivery unit
these women are more inclined to use second line labor
analgesia. Clearly, presence of the pain-protective SNP
combination of GCH1 does not contribute substantially
to our understanding of labor pain and has little to offer
in terms of individual counseling on labor analgesia.
Methods
Study population
Between March 1, 2007 and May 31, 2007 all women (age
> 18 years) attending the second trimester routine ultra-
sound screening at Uppsala University Hospital were
approached for study participation. In Sweden, all preg-
nant women are invited to an ultrasound examination at
16-18 weeks of gestation for estimation of the date of
childbirth and approximately 97 percent of the Swedish
pregnant population participate [19]. In Uppsala County,
all routine ultrasound examinations are performed at
Uppsala University Hospital which also is the only avail-
Table 3: Factors associated with use of second line labor analgesia
Use of second line 
labor analgesia
Unadjusted OR 95% CI Adjusted OR 95% CI
Parity Parous 130 (34.9%) 1 1
Nulliparous 222 (73.3%) 5.12*** 3.67 - 7.14 2.68*** 1.73 - 4.16
Height 0.98 0.96 - 1.00 0.98 0.96 - 1.00
Start of labor Spontaneous 291 (50.2%) 1 1
Induced 61 (63.5%) 1.73* 1.11 - 2.70 0.63 0.32 - 1.23
Cervical dilation at arrival 
to the delivery unit, cma
> 5 83 (36.9%) 1 1 0.79 - 0.97
2-4 178 (56.9%) 2.26*** 1.59 - 3.20 1.34 0.85 - 2.13
0-1 45 (78.9%) 6.42*** 3.21 - 12.82 2.46* 1.05 - 5.76
Duration of laborb 0-2 hours 32 (17.6%) 1 1
2-5 hours 74 (45.1%) 3.85*** 2.36 - 6.29 3.33*** 1.92 - 5.80
5-10 hours 109 (66.1%) 9.12*** 5.54 - 15.03 7.13*** 3.87 - 13.13
> 10 hours 134 (87.0%) 31.41*** 17.14 - 57.53 16.53*** 7.68 - 35.62
GCH1 pain protecting 
genotype
Absent 249 (51.8%) 1 1
Heterozygous 92 (51.1%) 0.97 0.69 - 137 1.25 0.80 - 1.97
Homozygous 11 (73.3%) 2.56 0.80 - 8.16 5.11* 1.09 - 23.96
a Missing cases 81
b Missing cases 11Dabo et al. Molecular Pain 2010, 6:41
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able delivery ward within the county. Hence, the study
subjects represent a population-based sample.
Exclusion criteria for the study were (1) detection of
malformation or missed abortion at the ultrasound exam-
ination, (2) inability to read and understand the study
information because of language difficulties, and (3) not
providing informed consent.
A blood sample was collected after the routine ultra-
sound examination in participating subjects.
Three months after delivery, the medical records of the
women were thoroughly reviewed. The labor pain behav-
ior related outcomes that were assessed in the study were
1) no use of analgesia during labor, 2) use of epidural
analgesia during labor, 3) use of any type of second line
analgesia, 4) stage of cervical dilation at arrival to the
delivery unit, and 5) stage of cervical dilation at request of
epidural analgesia. Second line labor analgesia was
defined as any use of more than one type of analgesia dur-
ing labor. Use of pudendus block (PDB) was not assessed
as it was impossible from the medical records to distin-
guish whether it was used during or after delivery. As
these outcomes are influenced by a number of confound-
ers, demographic data together with a number of obstet-
ric and delivery variables were also retrieved. Only cases
with complete medical records, live births and those who
had entered active phase of labor were included in the
study.
The participating women gave written informed con-
sent and the study was approved by the Independent Eth-
ical Review Board at Uppsala University, Sweden.
Sample collection
Blood samples were collected in tubes containing EDTA.
After collection the samples were put immediately on ice,
where they were kept for no longer than 2 h before they
were centrifuged for 10 minutes at 5000 rpm. Plasma and
buffy coat were separated and collected. The samples
were then stored at -70°C until analyzed.
DNA isolation
Total genomic DNA for the SNP genotyping assay was
extracted from whole blood using the Magtration 12GC
system (Precision System Science, Chiba, Japan) and the
Magazorb® DNA Common Kit-200 (Precision System Sci-
ence, Chiba, Japan) as described earlier [20]. From each
sample 200 μl whole blood was used and the final volume
of the DNA extract was 100 μl. The concentration of the
DNA was determined with Nanodrop Spectrophotome-
ter (Nanodrop Technologies Inc., Wilmington, DE, USA).
SNP genotyping
Three SNPs defined by Tegeder et al [14] as a pain-pro-
tective haplotype of GCH1 were used. The SNPs ana-
lyzed were c.-9610G > A (dbSNP rs8007267G > A),
c343+8900A > T (dbSNP rs3783641A > T) and c.*4279 >
G (dbSNP rs10483639C > G). The SNPs were determined
by TaqMan SNP genotyping assay (assay numbers
C_25800745, C_1545138 and C_3044867 respectively,
Applied Biosystems, Foster City, CA, USA). Briefly, the
assay included target-specific PCR primers and TaqMan
MGB probes labeled with two special dyes, FAM and
VIC. Applied Biosystems designed the primers and allele-
specific probes. To each well in a 384-well plate, genomic
DNA (5 ng), water, TaqMan Universal PCR master mix
and TaqMan genotyping assay mix was added, in a total
volume of 5ul. The genotyping was carried out, according
to the manufacturers' instructions, using the ABI7900HT
genetic detection system (Applied Biosystems) with the
following amplification protocol: 10 min at 95°C and 40
cycles of 15 s at 92°C and 1 min at 60°C.
Genotyping analyses
Genotyping was completed on 811 subjects. Among
them the numbers of homozygous carriers, heterozygous
carriers and non-carriers of the 3 SNPs used were in
accord with the Hardy-Weinberg equilibrium (c.-9610G >
A: x2 = 0.22, p = 0.65; c343+8900A > T: x2 = 0.35, p = 0.55;
c.*4279 > G: x2 = 0.0005, p = 0.98). The genotype frequen-
cies for c.-9610G > A were GG 67.6%, AG 28.9%, and AA
3.4%, for c343+8900A > T were AA 66.4%, AT 29.8%, and
TT 3.8% and for c.*4279 > G AA 65.3%, AT 31.0%, and
TT 3.7% respectively.
Statistical analyses
The study had a power of 80% to detect a difference in 1
cm on cervical dilation at arrival to the delivery unit with
500 women in the group of non-carriers compared to 200
women in the group of carriers (heterozygous and
homozygous) with an α-value of 0.05.
Demographic and obstetric variables were compared
between homozygous, heterozygous and non-carriers of
the pain-protective SNP combination by one-way analy-
sis of variance (ANOVA) and Tukey HSD or logistic
regression (with non-carriers as reference). Any signifi-
cant differences between groups were adjusted for rele-
vant confounders by analysis of covariance (ANCOVA)
or multivariate logistic regression.
Multivariate logistic regression analyses were used to
calculate unadjusted and adjusted odds ratios for use of
second line labour analgesia. The following maternal fac-
tors were analyzed: maternal age as completed years at
the time of the delivery, parity as primipara or not, mari-
tal status as married/cohabiting with a partner or other
marital status. Pre-pregnancy smoking, recorded at the
first visit to antenatal care, was categorized into non-
smoking (not daily smoking), and smoking (one or more
cigarettes per day). The first trimester height and weight
wer e used t o calcula t e body mass inde x (BMI), kg/m 2.Dabo et al. Molecular Pain 2010, 6:41
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Pregnancy and delivery data were categorized as follows:
gestational age according to the result of the second tri-
mester ultrasound screening, birth weight in grams, start
of labor as spontaneous or induced, duration of labor as
time from arrival in the delivery unit to parturition (cate-
gorized into quartiles), cervical dilation at arrival in the
delivery unit (categorized as 0-1 cm, 2-4 cm and more
than 5 cm), oxytocin use (yes/no). Only variables with
significant bivariate association with use of second line
analgesia (p < 0.25) were included in the final multivariate
model. Parous subjects were significantly older than nul-
liparous subjects (p < 0.001), and as parity was a stronger
explanatory variable it was used in the final model. Like-
wise, induced onset of labor and use of oxytocin were sig-
nificantly related (x2 = 61.6, p < 0.001) and for this reason,
only spontaneous onset of labor was used in the final
model. A two-sided p-value less than 0.05 was considered
as significant.
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